Impact of Voriconazole Therapeutic Drug Monitoring on Adverse Effects and Clinical Outcomes: A Literature Review
Ryan Clary, Erin Deja, Barry Rittmann, Gonzalo Bearman
Abstract
Abstract Purpose of Review Voriconazole is a broad-spectrum antifungal agent commonly used to treat severe fungal infections. Significant interindividual variability in drug metabolism can lead to subtherapeutic or toxic serum levels impacting clinical outcomes and risk for adverse effects. This review aims to summarize and evaluate evidence that assesses the impact of voriconazole therapeutic drug monitoring (TDM) on clinical outcomes and adverse effects. Recent Findings Many factors contribute to variability in serum voriconazole levels, such as CYP2C19 polymorphism, hepatic function, etc. TDM can aid in the management of narrow therapeutic index medications like voriconazole to optimize clinical outcomes. Current literature indicates that TDM improves clinical outcomes and reduces adverse effects by helping achieve therapeutic serum concentrations. Summary Voriconazole TDM is a valuable tool in optimizing treatment outcomes and minimizing adverse effects. Individualized dosing guided by TDM, helps achieve therapeutic serum levels, particularly in patients with variable metabolism enhancing the efficacy of treatment for invasive fungal infections.